AbbVie Inc. $ABBV Shares Sold by Essex LLC

Essex LLC trimmed its stake in AbbVie Inc. (NYSE:ABBV) by 42.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,233 shares of the company’s stock after selling 2,394 shares during the quarter. Essex LLC’s holdings in AbbVie were worth $703,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Brighton Jones LLC boosted its stake in AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares during the period. Revolve Wealth Partners LLC lifted its holdings in shares of AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. lifted its holdings in shares of AbbVie by 5.0% in the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after purchasing an additional 789 shares in the last quarter. Ieq Capital LLC boosted its position in shares of AbbVie by 4.6% in the second quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after buying an additional 5,274 shares during the period. Finally, Worldquant Millennium Advisors LLC boosted its position in shares of AbbVie by 117.3% in the second quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock worth $210,685,000 after buying an additional 612,702 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Performance

NYSE:ABBV opened at $251.07 on Thursday. The stock’s 50 day moving average price is $217.86 and its 200 day moving average price is $219.76. AbbVie Inc. has a 52 week low of $184.63 and a 52 week high of $255.99. The company has a market capitalization of $443.59 billion, a P/E ratio of 123.68, a P/E/G ratio of 0.83 and a beta of 0.32.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The firm had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company’s revenue was up 12.4% compared to the same quarter last year. During the same period in the previous year, the company earned $2.46 earnings per share. As a group, sell-side analysts forecast that AbbVie Inc. will post 14.28 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s payout ratio is presently 340.89%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ABBV. Morgan Stanley upped their price target on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Piper Sandler reiterated an “overweight” rating and issued a $298.00 target price on shares of AbbVie in a report on Tuesday, June 23rd. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.81.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported encouraging Phase 3 data for its venetoclax-based CLL treatment at the EHA 2026 Congress, reinforcing the drug’s safety and efficacy profile and supporting confidence in its hematology franchise.
• Positive Sentiment: AbbVie and Genmab’s lymphoma program met its primary endpoint in a Phase 3 trial, raising the odds of label expansion and a larger commercial opportunity for Epkinly.
• Positive Sentiment: News that AbbVie is acquiring Apogee Therapeutics has been viewed as a growth-supportive move, signaling continued pipeline expansion through M&A.
• Positive Sentiment: AbbVie also highlighted Aquipta’s efficacy for acute migraine following EU approval, adding another potential growth driver in its neuroscience portfolio.
• Neutral Sentiment: Analysts at Erste Group trimmed their FY2026 and FY2027 EPS estimates slightly, but the reductions were small and remained near consensus, so the impact looks limited.
• Negative Sentiment: US lawmakers opened an investigation into AbbVie and other drugmakers over clinical trials conducted in China, which could create headline risk and raise compliance concerns.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.